期刊文献+

口服缓控释制剂体外释放评价方法研究进展 被引量:10

Recent advances in the in vitro release study of oral sustained-release systems
原文传递
导出
摘要 口服缓控释制剂在胃肠道中停留转运的时间显著长于普通制剂,更易受胃肠道生理因素的影响。因此,研究和建立与体内相关的体外释放评价方法,对于保证口服缓控释制剂的内在质量非常重要。文中从装置、释放介质pH、表面活性剂、食物、乙醇等方面综述了近几年口服缓控释制剂体外释放的最新进展。 Since the oral sustained-release systems stay in the gastrointestinal tract (GIT) much longer, the drug release from the oral sustained-release systems is influenced easier by the physiological conditions of the GIT than that from the conventional preparations. For the quality control of the oral sustained-release systems, it is very important to study and establish in vitro release methods with a good in vivo and in vitro correlation. Based on relevant literature, improvements on the release conditions such as release apparatus, the pH value of release medi- um, surfactant, food and alcohol for in vitro release of oral sustained-release systems were reviewed.
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第2期196-200,共5页 Chinese Journal of New Drugs
基金 国家"重大新药创制"科技重大专项(2008ZXJ09010-001 2009ZX09301-002)
关键词 口服 缓控释制剂 体外释放 体内外相关性 释放装置 释放介质 oral sustained-release systems in vitro release in vivo/in vitro correlation release appara- tus release medium
  • 相关文献

参考文献2

二级参考文献24

  • 1张瑜,鲁清月,陈勇敢.5-氨基水杨酸缓释骨架片的研制[J].河南大学学报(医学版),2001,23(4):18-19. 被引量:1
  • 2朱盛山,袁旭江,李苑新.复方丹参缓释片中水溶性成分体外释放度研究[J].中国中药杂志,2006,31(1):37-40. 被引量:23
  • 3USP, United States Pharmacopeial Convention, Inc. , The United States 402 Pharmacopeia ( USP 31 ) [ S]. 2007:711.
  • 4Nunthanid J, Luangtana-ananM, Sriamomsak P, et al. Use of spray-drieg chitosan acetate and ethylcellulose as compression coats for colonic drudelivery : Effect of swelling on triggering in vitro drag release [ J ]. Eur J. Pharm. Biopharm. ,2009,71 (2) :356.
  • 5Wong D, Larrabee S, Clifford K, Tremblay J, et al. USP Dissolution Apparatus III( reciprocating cylinder) for screening of guar-based colonic delivery formulations [ J ]. J Controlled Release, 1997,47 ( 2 ) : 173- 179.
  • 6Klein S, Rudolph M W, Dressman J B, et al. Use of the BioDis to generate a physiologically relevant IVIVC [ J ]. J Controlled Release, 2008, 130(3) :216.
  • 7Joshi A, Pund S, Nivsarkar M, et al. Dissolution test for site-specific release isoniazid pellets in USP apparatus 3 ( reciprocating cylinder) : Optimization using response surface methodology [ J ]. Eur. J. Pharm. Biopharm. ,2008,69 ( 2 ) :769.
  • 8Trapani A, Laquintana V,Denora N ,et al. Eudragit RS 100 microparti- cles containing 2-hydroxypropyl-13-cyclodextrin and glutathione: Physi- cochemical characterization, drug release and transport studies [ J ]. European journal of pharmaceutical sciences,2007,30 ( 1 ) :64.
  • 9Ribeiro L, Ferreira D C, Veiga F J B. In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets [ J ]. J Controlled Release ,2005,103 (2) :325.
  • 10Mu Xiaohong,Tobyn M J , Staniforth J N. Development and evaluation of bio-dissolution systems capable of detecting the food effect on a polysaccharide-based matrix system [ J]. J Controlled Release, 2003,93 (3) :309.

共引文献33

同被引文献107

引证文献10

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部